MIRM
Mirum Pharmaceuticals, Inc. Common Stock
PHARMACEUTICAL PREPARATIONS
Best Pharmaceutical Stocks 2026 →
Mirum Pharmaceuticals (MIRM) Stock: Buy, Sell, or Hold?
$94.61
+0.19 (+0.20%)
▲
5d:
-2.43%
30d:
+18.83%
90d:
-4.21%
Open in Live Scanner
70/30 Portfolio Builder
Earnings: Nov 03, 2026
0d
Protect MIRM Gains
Updated Nov 11, 12:00 AM ET
QUANTITATIVE VERDICT
WAIT
LOW Confidence (23%)
Quality Score
40/100
Position
EXTENDED
30-Day Fair Range
$80.63 – $88.71
Position: EXTENDED
Forward P/E & Valuation
295.7x
STRETCHED
vs 203.2x historical avg
Wall Street Target
$156.92
+65.9% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$83.13 / $98.97
Trend: Strong Downtrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
📊 MIXED SIGNALS: MIRM shows conflicting indicators. Wait for confirmation before entering.
Get Alerted When MIRM Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$11.21
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$6.96
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: MIRM is currently trading at $94.61, which is considered extended relative to its 30-day fair value range of $80.63 to $88.71. From a valuation perspective, the stock is trading at a premium (Forward PE: 295.7) compared to its historical average (203.2). At these levels, the market is pricing in 13.3% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, MIRM is in a strong downtrend. Immediate support is located at $83.13, while resistance sits at $98.97.
Market Sentiment: MIRM scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $156.92 (+65.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, MIRM is in a strong downtrend. Immediate support is located at $83.13, while resistance sits at $98.97.
Market Sentiment: MIRM scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $156.92 (+65.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$80.63 -
$88.71
Company Quality Score
40/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
22.9%
Trading Range & Key Levels
30-Day Trading Range
$80.63 -
$88.71
Current vs Trading Range
EXTENDED
Support Level
$83.13
Resistance Level
$98.97
Current Trend
Strong Downtrend
Technical data as of
Nov 11, 2026
Protect Your Profits
Holding MIRM? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanQuantitative Signal Breakdown
- BEARISH: Price extended above range (+6.7% above its trading range)
- BEARISH: Weak technical setup (0/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 65.9% below Wall St target ($156.92)
- NEUTRAL: Trading at premium valuation - market expects 13.3% growth which is achievable
- WARNING: Composite score 40/100 in the bottom quintile — this cohort historically lags the market
Fundamental Context
Forward P/E (Next Year Est.)
295.66
Wall Street Target
$156.92
(+65.9%)
Revenue Growth (YoY)
39.6%
Profit Margin
-134.8%
Valuation Premium vs History
+13.3% premium
PE vs Historical
295.7 vs 203.2
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+13.3%
(market-implied from PE analysis)
1-Year Target
$107.19
(+13%)
2-Year Target
$121.45
(+28%)
3-Year Target
$137.60
(+45%)
3-Yr Target (if PE normalizes)
(PE: 296→203)
PE COMPRESSION
$94.57
(0%)
Earnings growth offset by PE compression
Share MIRM Analysis
Share this live MIRM analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (MIRM)
Bullish
3 Retail Mentions
Reddit / WSB Comments
1
Bullish
StockTwits Volume
2 msgs
24h retail stream
Last Tracked
Nov 10, 2026
Daily AI digest
AI Retail Discussion Summary:
Investors express bullish sentiment towards $MIRM following positive clinical trial results for its hepatitis D treatment and confidence in NDA approval, as reflected in a Yahoo Finance article reporting a 'clean win' for a Gilead rival.
Key Retail Themes:
Positive clinical trial results
NDA approval expectations
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 12, 2026 1:37 AM ET
Data refreshes hourly during market hours. Next update: 2:37 AM
Data refreshes hourly during market hours. Next update: 2:37 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MIRM showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
CYTK
Cytokinetics Inc |
STRONG BUY
22 analysts |
$107 | 61 BUY |
|
INSM
Insmed Inc |
STRONG BUY
24 analysts |
$194 | 37 SELL |
|
MDGL
Madrigal Pharmaceuticals… |
STRONG BUY
19 analysts |
$689 | 56 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$86 | 46 HOLD |
|
RCUS
Arcus Biosciences Inc |
STRONG BUY
15 analysts |
$41 | 63 BUY |
Advanced MIRM Option Strategies
Professional options setups generated by AI based on today's MIRM price and gamma walls.
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive MIRM Research Pages
